论文部分内容阅读
为寻找可用于抗移植排斥反应的新药，作者对复方华西Ⅰ号中药抗兔甲状腺移植排斥反应的机理进行了研究。实验采用兔甲状腺全切制成的甲低模型，再于预前肌组中移植甲状腺组织。结果发现术后第２１天和２８天，华西Ｉ号组和地塞米松组的Ｔ３、Ｔ４接近，均明显高于对照组，其组织病理改变和功能检查结果相吻合，表明华西Ⅰ号和地塞米松均可对抗甲状腺移植排斥反应，但地塞米松副作用较强；华西Ⅰ号的作用机理具有进一步研究的价值。
In order to find a new drug that can be used for anti-transplantation rejection, the authors studied the mechanism of anti-rabbit thyroid graft rejection of Compound Huaxi No. I. A hypothyroid model of rabbit thyroid glands was used in the experiment, and thyroid tissue was transplanted in the pre-muscle group. The results showed that on the 21st and 28th days after operation, T3 and T4 were similar in the Huaxi Group I and dexamethasone groups, which were significantly higher than those in the control group. Their histopathological changes and functional examinations were consistent with each other, indicating that Huaxi I and the ground were the same. Dexamethasone can resist thyroid allograft rejection, but dexamethasone has stronger side effects; the mechanism of action of Huaxi I has further research value.